[1]张明 刘德敏 崔炜.肝素诱导的血小板减少症治疗的研究进展[J].心血管病学进展,2019,(9):1219-1223.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.009]
　ZHANG Ming,LIU Demin,CUI Wei.Teparin-induced Thrombocytopenia Treatment[J].Advances in Cardiovascular Diseases,2019,(9):1219-1223.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.009]
点击复制

肝素诱导的血小板减少症治疗的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2019年9期
页码:
1219-1223
栏目:
综述
出版日期:
2019-12-25

文章信息/Info

Title:
Teparin-induced Thrombocytopenia Treatment
作者:
张明 刘德敏 崔炜
河北医科大学第二医院 河北省心脑血管病研究所心内一科,石家庄050000
Author(s):
ZHANG Ming;  LIU Demin;  CUI Wei
(First Division, Department of Cardiology, The Second Hospital of Hebei Medical University and Institute of Cardiocerebrovascular Disease of Hebei Province, Shijiazhuang 050000, Hebei, China)
关键词:
肝素诱导的血小板减少症; 治疗; 研究进展
Keywords:
Teparin-induced thrombocytopenia;  Treatment;  Research progress
DOI:
10.16806/j.cnki.issn.1004-3934.2019.09.009
摘要:
肝素诱导的血小板减少症是一种罕见的血栓前的药物反应，由抗血小板因子4抗体，即一种肝素依赖的IgG特异性抗体通过与血小板Fc受体结合而激活血小板，最终导致可能的肢体坏死或危及生命的血栓栓塞等并发症。目前主要的治疗选择包括阿加曲班、达那肝素和比伐芦定等胃肠外抗凝药物。然而近些年来，新型口服抗凝药、静注人免疫球蛋白以及血浆置换等新兴治疗方法不断引起人们的关注。对肝素诱导的血小板减少症治疗的研究进展一概述。
Abstract:
Heparin-induced thrombocytopenia (HIT) is a rare prethrombotic drug response that binds to platelet Fc receptors by an anti-platelet factor 4 antibody that is a heparin-dependent IgG-specific antibody. Activation of platelets ultimately leads to complications such as possible limb necrosis or life-threatening thromboembolism. Current major treatment options include parenteral anticoagulants such as argatroban, danapaparin, and bivalirudin. However, in recent years, new oral anticoagulants, intravenous immunoglobulins, and plasmapheresis have been emerging. This article aims to provide an overview of the research progress in HIT treatment

参考文献/References:

[1] Greinacher A. Heparin-nduced thrombocytopenia[J]. N Engl J Med,2015, 373(19):1883-1884.
[2] Warkentin TE, Safyan EL, Linkins LA. Heparin-induced thrombocytopenia presenting as bilateral adrenal hemorrhages[J].N Engl J Med,2015,372(5): 492-494.
[3] Goel R, Ness PM, Takemoto CM, et al. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality[J].Blood,2015,125(9):1470-1476.
[4] Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest,2012,141(2 Suppl): e495S-530S.
[5] Alatri A, Armstrong AE, Greinacher A, et al. Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - a European Perspective[J]. Thromb Res,2012,129(4):426-433.
[6] Schindewolf M, Steindl J, Beyer-Westendorf J, et al. Use of fondaparinux off-label or approved anticoagulants for management of heparin-induced thrombocytopenia[J]. J Am Coll Cardiol,2017,70(21): 2636-2648.
[7] Kang M, Alahmadi M, Sawh S, et al. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study[J]. Blood,2015,125(6):924-929.
[8] Bhatt VR, Aryal MR, Shrestha R, et al.Fondaparinux-associated heparin-induced thrombocytopenia[J]. Eur J Haematol,2013,91(5): 437-441.
[9] 中国医师协会心血管内科医师分会血栓防治专业委员会, 《中华医学杂志》编辑委员会. 肝素诱导的血小板减少症中国专家共识(2017)[J]. 中华医学杂志, 2018,(6):408-417.
[10] Tvito A, Bakchoul T, Rowe JM, et al. Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment[J]. Am J Hematol,2015, 90(7): 675-678.
[11] Warkentin TE. Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia[J].Thromb Haemost,2016,116(5): 813-822.
[12] Poudel DR, Ghimire S, Dhital R, et al. Spontaneous HIT syndrome post-knee replacement surgery with delayed recovery of thrombocytopenia: a case report and literature review[J]. Platelets,2017,28(6):614-620.
[13] Franchini M, Liumbruno GM, Bonfanti C, et al.The evolution of anticoagulant therapy[J]. Blood Transfus,2016,14(2):175-184.
[14] Krauel K, Hackbarth C, Furll B, et al. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies[J]. Blood,2012, 119(5): 1248-1255.
[15] Miyares MA, Davis KA. Direct-acting oral anticoagulants as emerging treatment options for heparin-induced thrombocytopenia[J].Ann Pharmacother, 2015, 49(6): 735-739.
[16] Vavlukis M, Kotlar I, Taravari H, et al.Can rivaroxaban be a drug of choice for treating heparin-induced thrombocytopenia in a patient with pulmonary thromboembolism[J]. Anatol J Cardiol,2017,18(1):77-79.
[17] Tardy-Poncet B, Piot M, Montmartin A, et al. Delayed-onset heparin-induced thrombocytopenia without thrombosis in a patient receiving postoperative thromboprophylaxis with rivaroxaban[J].Thromb Haemost,2015,114(3): 652-654.
[18] Abouchakra L, Khabbaz Z, Abouassi S, et al. Rivaroxaban for treatment of heparin-induced thrombocytopenia after cardiac surgery: A case report[J]. J Thorac Cardiovasc Surg,2015,150(2): e19-20.
[19] Linkins LA, Warkentin TE, Pai M, et al. Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study[J]. J Thromb Haemost,2016,14(6):1206-1210.
[20] Warkentin TE, Pai M, Linkins LA. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review[J]. Blood,2017, 130(9): 1104-1113.
[21] Kopolovic I, Warkentin TE. Progressive thrombocytopenia after cardiac surgery in a 67-year-old man[J]. CMAJ,2014,186(12): 929-933.
[22] Ng HJ, Than H, Teo EC. First experiences with the use of rivaroxaban in the treatment of heparin-induced thrombocytopenia[J]. Thromb Res,2015,135(1): 205-207.
[23] Ong SY, Chin YA, Than H, et al. Rivaroxaban for heparin-induced thrombocytopenia: adding to the evidence[J].Ann Hematol,2017,96(3): 525-527.
[24] Sharifi M, Bay C, Vajo Z, et al. New oral anticoagulants in the treatment of heparin-induced thrombocytopenia[J]. Thromb Res,2015,135(4): 607-609.
[25] Hantson P, Lambert C, Hermans C. Rivaroxaban for arterial thrombosis related to heparin-induced thrombocytopenia[J]. Blood Coagul Fibrinolysis, 2015,26(2): 205-206.
[26] Sartori M, Favaretto E, Cini M, et al. Rivaroxaban in the Treatment of Heparin-Induced Thrombocytopenia[J]. J Thromb Thrombolysis,2015,40(3): 392-394.
[27] Casan JM,Grigoriadis G, Chan N,et al. Rivaroxaban in treatment refractory heparin-induced thrombocytopenia[J]. BMJ Case Rep,2016,2016:pii: bcr2016216110.
[28] Samo? M, Bolek T, Ivanková J, et al. Heparin-induced Thrombocytopenia Presenting With Deep Venous Thrombosis and Pulmonary Embolism Successfully Treated With Rivaroxaban: Clinical Case Report and Review of Current Experiences[J]. J Cardiovasc Pharmacol,2016, 68(5): 391-394.
[29] Kuter DJ, Konkle BA, Hamza TH, et al. Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia[J]. Am J Hematol,2017,92(8): 730-738.
[30] Padmanabhan A, Jones CG, Pechauer SM, et al. IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia[J].Chest,2017,152(3): 478-485.
[31] Ammann EM, Haskins CB, Fillman KM, et al. Intravenous immune globulin and thromboembolic adverse events: A systematic review and meta-analysis of RCTs[J]. Am J Hematol,2016,91(6): 594-605.
[32] Warkentin TE, Sheppard JA. Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin[J]. Blood,2014,123(16): 2485-2493.
[33] Azimov MB, Slater ED. Persistent heparin-induced thrombocytopenia treated with IVIg[J]. Chest,2017,152(3): 679-680.
[34] Ibrahim IF, Rice L. Intravenous immunoglobulin for heparin-induced thrombocytopenia[J]. Chest,2017,152(4): 906-907.
[35] Warkentin TE, Climans TH, Morin PA. Intravenous immune globulin to prevent heparin-induced thrombocytopenia[J]. N Engl J Med,2018,378(19): 1845-1848.
[36] Schwartz J, Winters JL, Padmanabhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue[J]. J Clin Apher,2013,28(3): 145-284.
[37] Iluonakhamhe E, Ibekwe O, Samuel S, et al. Plasmapheresis may be an option in urgent management of heparin-induced thrombocytopenia in the setting of acute intracerebral hemorrhage[J]. Neurocrit Care,2015,22(1): 140-145.
[38] Welsby IJ, Um J, Milano CA, et al. Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia[J]. Anesth Analg,2010,110(1):30-35.
[39] Warkentin TE, Sheppard JA, Chu FV, et al. Plasma exchange to remove HIT antibodies: dissociation between enzyme-immunoassay and platelet activation test reactivities[J]. Blood,2015,125(1):195-198.
[40] Ramu B, Cogswell RJ, Reding MT, et al. Plasma exchange to remove heparin-induced thrombocytopenia antibodies and the use of heparin during cardiopulmonary bypass in critically ill cardiac patients[J]. J Heart Lung Transplant,2018,37(8): 1038-1040.

相似文献/References:

[1]潘甜 马康华.急性心肌梗死经皮冠脉介入术后冠状动脉无复流的预防和治疗进展[J].心血管病学进展,2019,(5):730.[doi:10.16806/j.cnki.issn.1004-3932019.05.017]
　PAN Tian,MA Kanghua.Prevention and Treatment of Coronary Artery No-Reflow after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(9):730.[doi:10.16806/j.cnki.issn.1004-3932019.05.017]
[2]雷亚莉 熊峰.心室憩室的诊治进展[J].心血管病学进展,2019,(8):1154.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.021]
　LEI Yali,XIONG Feng.Diagnosis and Treatment of Ventricular Diverticulum[J].Advances in Cardiovascular Diseases,2019,(9):1154.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.021]
[3]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
　LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[4]朱永翔 李烽 张耀庭 陆丽洁 龙明智.沙库巴曲缬沙坦在射血分数降低性心力衰竭患者治疗中的研究进展[J].心血管病学进展,2019,(9):1249.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.016]
　ZHU Yongxiang,LI Feng,ZHANG Yaoting,et al.Sacubitril-valsartan for Heart Failure with Reduced Ejection Fraction[J].Advances in Cardiovascular Diseases,2019,(9):1249.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.016]
[5]夏熠 刘飞 夏云龙.糖尿病合并心房颤动的相关研究进展[J].心血管病学进展,2020,(1):27.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.008]
　XIA YiLIU FeiXIA Yunlong.Research Progress in Diabetes Mellitus Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(9):27.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.008]
[6]刘磊 杨震.心肌梗死后左心室壁瘤相关室性心律失常的形成机制与治疗进展[J].心血管病学进展,2020,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.013]
　LIU Lei,YANG Zhen.Mechanism and Progress in Treatment of Post-infarction Left Ventricular Aneurysm with Ventricular Arrhythmias[J].Advances in Cardiovascular Diseases,2020,(9):46.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.013]
[7]黄巧娟 周晓莉.冠状动脉慢血流现象的研究进展[J].心血管病学进展,2020,(2):163.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.016]
　HUANG QiaojuanZHOU Xiaoli.Coronary Slow Flow Phenomenon[J].Advances in Cardiovascular Diseases,2020,(9):163.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.016]
[8]毛玉琳 何胜虎.2型糖尿病和慢性心力衰竭[J].心血管病学进展,2020,(5):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
　MAO Yulin,HE Shenghu.Type 2 Diabetes Mellitus and Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2020,(9):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
[9]张艺文 汪汉 秦莉 杨晓倩 童兰 蔡琳.狼疮患者冠心病的诊断、风险评估和治疗[J].心血管病学进展,2020,(5):513.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.017]
　ZHANG Yiwen,WANG Han,QIN Li,et al.Diagnosis, Risk Evaluation and Therapy of Coronary Heart Disease in Lupus Patients[J].Advances in Cardiovascular Diseases,2020,(9):513.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.017]
[10]阿依尼尕尔·马木提 周贤惠.光遗传学技术在心律失常研究中的应用及进展[J].心血管病学进展,2020,(7):687.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.004]
　Ayinigaer·Mamuti,ZHOU Xianhui.Application and Progress of Optogenetics in Study of Cardiac Arrhythmias[J].Advances in Cardiovascular Diseases,2020,(9):687.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.004]

更新日期/Last Update: 2020-02-06